Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 2/20 | 0.65 |
| ▸ | PRMT6 | Q96LA8 | 2/20 | 0.65 |
| ▸ | PRMT8 | Q9NR22 | 2/20 | 0.65 |
| ▸ | CXCR4 | P61073 | 8/20 | 0.57 |
| ▸ | RAD52 | P43351 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.47 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.42 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.42 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | CCR2 | P41597 | 1/20 | 0.42 |
| ▸ | CXCL12 | P48061 | 1/20 | 0.42 |
| ▸ | BLM | P54132 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL681608 | 0.92 | CARM1 (0.62) | CARM1PRMT6PRMT8CXCR4RAD52 | |
| SCHEMBL24971199 | 0.81 | CXCR4 (0.58) | CARM1PRMT6PRMT8CXCR4RAD52 | |
| SCHEMBL5573157 | 0.80 | CXCR4 (0.74) | CXCR4RAD52HSD17B10MEN1KMT2A | |
| SCHEMBL474948 | 0.80 | — | — | |
| SCHEMBL23337601 | 0.80 | CXCR4 (0.74) | CXCR4RAD52HSD17B10MEN1KMT2A | |
| SCHEMBL9927938 | 0.80 | — | — | |
| SCHEMBL18427337 | 0.80 | CARM1 (0.48) | CARM1PRMT6PRMT8CXCR4RAD52 | |
| SCHEMBL25568895 | 0.80 | CARM1 (0.48) | CARM1PRMT6PRMT8CXCR4RAD52 | |
| SCHEMBL2918767 | 0.79 | CXCR4 (0.50) | CARM1PRMT6PRMT8CXCR4RAD52 | |
| SCHEMBL928301 | 0.79 | CXCR4 (0.50) | CARM1PRMT6PRMT8CXCR4RAD52 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1591443-B1 | PYRAZOLE DERIVATIVE | DAIICHI SANKYO CO LTD (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-7622471-B2 | Pyrazole derivatives having a pyridazine and pyridine functionality | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2009-11-24 | — | — | US | disclosed |
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-05-29 | — | — | US | disclosed |
| US-20080064682-A1 | Pyrazole Derivatives | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2008-03-13 | — | — | US | disclosed |
| US-20070254881-A1 | Pyrazole Derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-11-01 | — | — | US | disclosed |
| EP-1803719-A1 | 1,5-DIHETEROCYCLE-1H-TRIAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-07-04 | — | — | EP | disclosed |
| EP-1785418-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-05-16 | — | — | EP | disclosed |
| EP-1762568-A1 | PYRAZOLE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-03-14 | — | — | EP | disclosed |
| US-20060189591-A1 | Five-membered heterocyclic derivative | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2006-08-24 | — | — | US | disclosed |
| US-20060128685-A1 | Pyrazole derivative | DAIICHI PHARMACEUTICAL CO., LTD., (JP) | 2006-06-15 | — | — | US | disclosed |
| EP-1591443-A1 | PYRAZOLE DERIVATIVE | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2005-11-02 | — | — | EP | disclosed |
| EP-0595557-B1 | New substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO INC (US) | 2004-06-30 | — | — | EP | disclosed |
| CN-1043884-C | Substituted azetidinones, process for their preparation and their use as medicaments | MERCK & CO INC (US) | 1999-06-30 | — | — | CN | disclosed |
| US-5747485-A | RESPIRATORY SYSTEM DISORDERS | MERCK & CO., INC. (US) | 1998-05-05 | — | — | US | disclosed |
| EP-0755262-A4 | COMPOSITION FOR THE TREATMENT OF LUNG DISEASE | MERCK & CO INC (US) | 1997-05-07 | — | — | EP | disclosed |
| EP-0755262-A1 | COMPOSITION FOR THE TREATMENT OF LUNG DISEASE | MERCK & CO. INC. (US) | 1997-01-29 | — | — | EP | disclosed |
| US-5591737-A | ELASTASE INHIBITORS | MERCK & CO., INC. (US) | 1997-01-07 | — | — | US | disclosed |
| WO-1995024207-A1 | COMPOSITION FOR THE TREATMENT OF LUNG DISEASE | MERCK & CO., INC. (US) | 1995-09-14 | — | — | WO | disclosed |
| WO-1994010142-A1 | NEW SUBSTITUTED AZETIDINONES AS ANTI-INFLAMMATORY AND ANTIDEGENERATIVE AGENTS | MERCK & CO., INC. (US) | 1994-05-11 | — | — | WO | disclosed |
| EP-0595557-A1 | New substituted azetidinones as anti-inflammatory and antidegenerative agents | MERCK & CO. INC. (US) | 1994-05-04 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125409-A1 | 1,5-Diheterocycle-1H-Triazole Derivative | PTGS1, PTGER1, TBXA2R | CARM1 1940/4885PRMT6 3126/4885PRMT8 3173/4885 |
| US-20070254881-A1 | Pyrazole Derivative | PTGER1, PTGS1, PTGER2 | CARM1 2231/4885PRMT6 3155/4885PRMT8 3316/4885 |
| US-20060128685-A1 | Pyrazole derivative | PTGS1, PTGS2, PTGER1 | CARM1 4606/4885PRMT6 4603/4885PRMT8 4702/4885 |
| US-20080064682-A1 | Pyrazole Derivatives | NAT1, AR, CBR3 | CARM1 79/4885PRMT6 679/4885PRMT8 796/4885 |
| US-20060189591-A1 | Five-membered heterocyclic derivative | PTGS1, PTGIS, PTGS2 | CARM1 4632/4885PRMT6 4661/4885PRMT8 4561/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.